Solutions
Digital Cognitive Assessment
Endpoint Data Quality (Rater Services)
Remote Assessment
Scientific Consulting
Healthcare Cognitive Screening
Research and Academic Collaborations
Therapeutic Expertise
Alzheimer’s Disease and Dementia
Preclinical Alzheimer’s Disease
Pediatrics & Rare Disease
Parkinson’s Disease
Multiple Sclerosis
Schizophrenia
Oncology
Safety
Sleep Disorders
Mood Disorders
Resources
Fact Sheets
Webinars
Posters
Publications
Blog
Company
About Cogstate
Leadership Teams
Clinical & Scientific Network (LEADs)
Company News
Careers & Life at Cogstate
CTAD 2024
Investor Centre
Corporate Governance
Board of Directors
ASX Announcements & Share Price
Financial Reports
Investor Presentations
Financial Calendar
Shareholder Information
Contact Us
Support
Solutions
Digital Cognitive Assessment
Endpoint Data Quality (Rater Services)
Remote Assessment
Scientific Consulting
Healthcare Cognitive Screening
Research and Academic Collaborations
Therapeutic Expertise
Alzheimer’s Disease and Dementia
Preclinical Alzheimer’s Disease
Pediatrics & Rare Disease
Parkinson’s Disease
Multiple Sclerosis
Schizophrenia
Oncology
Safety
Sleep Disorders
Mood Disorders
Resources
Fact Sheets
Webinars
Posters
Publications
Blog
Company
About Cogstate
Leadership Teams
Clinical & Scientific Network (LEADs)
Company News
Careers & Life at Cogstate
CTAD 2024
Investor Centre
Corporate Governance
Board of Directors
ASX Announcements & Share Price
Financial Reports
Investor Presentations
Financial Calendar
Shareholder Information
Contact Us
Support
Webinars
Learn valuable perspectives by watching presentations from industry panelists.
Search
Show All
December 10, 2024
Navigating the CNS Clinical Trial Landscape in the Asia-Pacific (APAC): Challenges, Opportunities, and Best Practices
November 20, 2024
Utilizing the Measurement of Cognition to Determine Drug Safety in Late Phase Clinical Trials
October 23, 2024
Addressing Complexity in CNS Trial Endpoints by Leveraging an Integrated eCOA and Rater Training Approach
October 3, 2024
Developmental & Epileptic Encephalopathy (DEE) Trials: Optimizing Endpoints, Determining MCID, and Enhancing Trial Data Quality
April 30, 2024
Using Cognition to Understand Effects of Medicines Used to Optimize Sleep or Wakefulness
February 8, 2024
Strategic Design Decisions in Rare Disease Trials | Adapting Endpoints, Ensuring Data Quality, and Determining Clinical Meaningfulness of Trial Results
October 18, 2023
Improve Data Reliability from MADRS and HAM-D Assessments in Clinical Trials: Scientific and Operational Recommendations
April 26, 2023
Capturing a Comprehensive Picture of Parkinsonian Symptoms, Reflective of Importance to Patients, Across Motor, Cognitive & Behavioral Impairments
March 22, 2023
Improving Data Quality and Reducing Site/Patient Burden in Remote Rare Disease Trials
December 15, 2022
Bringing the Clinical Trial to the Patient in Preclinical Alzheimer’s Disease
June 16, 2022
Cultural-Linguistic Considerations for Successful Cognitive Endpoint Assessment in International CNS Clinical Trials
March 30, 2022
CNS Safety of Drugs in Late Phase Clinical Trials: Using Cognitive Information in Discussions with Regulators
March 9, 2022
Leveraging Remote Assessments and Central Raters to Optimize Rare Disease Clinical Trials
November 4, 2021
Implementing Decentralized Clinical Trials in CNS: Cognitive and Clinical Assessments
June 10, 2021
Clinical Trials of Schizophrenia: Optimizing Patient Reported Outcomes and Performance Outcome Assessments
How can we help you optimize the measurement of brain health?
Contact Our Team
We use cookies to analyze our website traffic and to support technical features that enhance your user experience. Read our
Privacy
and
Cookie
Policies to learn more about how we use cookies.
Accept Cookies
Decline Cookies